

Paul W Burridge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2210625/publications.pdf>

Version: 2024-02-01

75
papers

7,153
citations

101496

36
h-index

82499

72
g-index

80
all docs

80
docs citations

80
times ranked

9417
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity. <i>Circulation</i> , 2022, 145, 279-294.	1.6	46
2	Letter by Costantine et al Regarding Article, "Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia". <i>Circulation</i> , 2022, 145, e115-e116.	1.6	1
3	Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility. <i>Nature Genetics</i> , 2022, 54, 232-239.	9.4	55
4	Prime time for doxorubicin-induced cardiotoxicity genetic testing. <i>Pharmacogenomics</i> , 2022, 23, 335-338.	0.6	0
5	A Novel Locus on 6p21.2 for Cancer Treatment-Induced Cardiac Dysfunction Among Childhood Cancer Survivors. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1109-1116.	3.0	4
6	Genetic Variants Associated with Therapy-Related Cardiomyopathy among Childhood Cancer Survivors of African Ancestry. <i>Cancer Research</i> , 2021, 81, 2556-2565.	0.4	24
7	Structural and Functional Characterization of a Na ^v 1.5-Mitochondrial Couplon. <i>Circulation Research</i> , 2021, 128, 419-432.	2.0	15
8	Cellular model systems to study cardiovascular injury from chemotherapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 890-896.	1.0	8
9	Targeting OCT3 attenuates doxorubicin-induced cardiac injury. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	33
10	Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity. <i>Pharmacogenomics</i> , 2021, 22, 41-54.	0.6	4
11	An updated protocol for the cost-effective and weekend-free culture of human induced pluripotent stem cells. <i>STAR Protocols</i> , 2021, 2, 100213.	0.5	5
12	Targeting the Microtubule EB1-CLASP2 Complex Modulates Na ^v 1.5 at Intercalated Discs. <i>Circulation Research</i> , 2021, 129, 349-365.	2.0	23
13	RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy. <i>Cell Stem Cell</i> , 2021, 28, 2076-2089.e7.	5.2	36
14	Doxorubicin-Induced Ascension of Resident Cardiac Macrophages. <i>Circulation Research</i> , 2020, 127, 628-630.	2.0	1
15	GS-967 and Eleclazine Block Sodium Channels in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Molecular Pharmacology</i> , 2020, 98, 540-547.	1.0	17
16	Lymphoangiocrine signals promote cardiac growth and repair. <i>Nature</i> , 2020, 588, 705-711.	13.7	103
17	Association of <i>GSTM1</i> null variant with anthracycline-related cardiomyopathy after childhood cancer: A Children's Oncology Group ALTE03N1 report. <i>Cancer</i> , 2020, 126, 4051-4058.	2.0	23
18	Generating a Cost-Effective, Weekend-Free Chemically Defined Human Induced Pluripotent Stem Cell (hiPSC) Culture Medium. <i>Current Protocols in Stem Cell Biology</i> , 2020, 53, e110.	3.0	1

#	ARTICLE	IF	CITATIONS
19	Silencing of <i>MYH7</i> ameliorates disease phenotypes in human iPSC-cardiomyocytes. <i>Physiological Genomics</i> , 2020, 52, 293-303.	1.0	29
20	Pluripotent Stem Cell Modeling of Anticancer Therapy-Induced Cardiotoxicity. <i>Current Cardiology Reports</i> , 2020, 22, 56.	1.3	2
21	Precise and Cost-Effective Nanopore Sequencing for Post-GWAS Fine-Mapping and Causal Variant Identification. <i>IScience</i> , 2020, 23, 100971.	1.9	7
22	Human In Vitro Models for Assessing the Genomic Basis of Chemotherapy-Induced Cardiovascular Toxicity. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 377-389.	1.1	11
23	Negligible-Cost and Weekend-Free Chemically Defined Human iPSC Culture. <i>Stem Cell Reports</i> , 2020, 14, 256-270.	2.3	80
24	Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association. <i>Circulation Research</i> , 2019, 125, e75-e92.	2.0	103
25	Genetic Mosaicism in Calmodulinopathy. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, 375-385.	1.6	33
26	Are These Cardiomyocytes? Protocol Development Reveals Impact of Sample Preparation on the Accuracy of Identifying Cardiomyocytes by Flow Cytometry. <i>Stem Cell Reports</i> , 2019, 12, 395-410.	2.3	14
27	hiPSCs in cardio-oncology: deciphering the genomics. <i>Cardiovascular Research</i> , 2019, 115, 935-948.	1.8	21
28	Unraveling Difficult Answers: From Genotype to Phenotype in Coronary Artery Disease. <i>Cell Stem Cell</i> , 2019, 24, 203-205.	5.2	5
29	Late onset heart failure after childhood chemotherapy. <i>European Heart Journal</i> , 2019, 40, 798-800.	1.0	18
30	Stage-specific Effects of Bioactive Lipids on Human iPSC Cardiac Differentiation and Cardiomyocyte Proliferation. <i>Scientific Reports</i> , 2018, 8, 6618.	1.6	32
31	Passive Stretch Induces Structural and Functional Maturation of Engineered Heart Muscle as Predicted by Computational Modeling. <i>Stem Cells</i> , 2018, 36, 265-277.	1.4	111
32	Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems. <i>Annual Review of Pharmacology and Toxicology</i> , 2018, 58, 83-103.	4.2	89
33	The future role of pharmacogenomics in anticancer agent-induced cardiovascular toxicity. <i>Pharmacogenomics</i> , 2018, 19, 79-82.	0.6	10
34	Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity. <i>Nature Protocols</i> , 2018, 13, 3018-3041.	5.5	102
35	Doxorubicin induces caspase-mediated proteolysis of KV7.1. <i>Communications Biology</i> , 2018, 1, 155.	2.0	5
36	High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	297

#	ARTICLE	IF	CITATIONS
37	Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor- β^2 and Cardiac Fibrosis. <i>Circulation</i> , 2017, 136, 664-679.	1.6	64
38	Accurate nanoelectrode recording of human pluripotent stem cell-derived cardiomyocytes for assaying drugs and modeling disease. <i>Microsystems and Nanoengineering</i> , 2017, 3, 16080.	3.4	49
39	Acute CD47 Blockade During Ischemic Myocardial Reperfusion Enhances Phagocytosis-Associated Cardiac Repair. <i>JACC Basic To Translational Science</i> , 2017, 2, 386-397.	1.9	40
40	Sirtuin 2 regulates cellular iron homeostasis via deacetylation of transcription factor NRF2. <i>Journal of Clinical Investigation</i> , 2017, 127, 1505-1516.	3.9	101
41	Generation and Application of Human Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Cardiac and Vascular Biology</i> , 2017, , 67-106.	0.2	0
42	Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. <i>Nature Medicine</i> , 2016, 22, 547-556.	15.2	573
43	Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?. , 2016, 168, 113-125.		61
44	Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro. <i>Cell Stem Cell</i> , 2016, 19, 311-325.	5.2	131
45	Chemically Defined Culture and Cardiomyocyte Differentiation of Human Pluripotent Stem Cells. <i>Current Protocols in Human Genetics</i> , 2015, 87, 21.3.1-21.3.15.	3.5	112
46	Derivation of Highly Purified Cardiomyocytes from Human Induced Pluripotent Stem Cells Using Small Molecule-modulated Differentiation and Subsequent Glucose Starvation. <i>Journal of Visualized Experiments</i> , 2015, , .	0.2	68
47	Genetic and Epigenetic Regulation of Human Cardiac Reprogramming and Differentiation in Regenerative Medicine. <i>Annual Review of Genetics</i> , 2015, 49, 461-484.	3.2	63
48	Modeling Cardiovascular Diseases with Patient-Specific Human Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Methods in Molecular Biology</i> , 2015, 1353, 119-130.	0.4	35
49	Novel codon-optimized mini-intronic plasmid for efficient, inexpensive and xeno-free induction of pluripotency. <i>Scientific Reports</i> , 2015, 5, 8081.	1.6	51
50	Pravastatin reverses obesity-induced dysfunction of induced pluripotent stem cell-derived endothelial cells via a nitric oxide-dependent mechanism. <i>European Heart Journal</i> , 2015, 36, 806-816.	1.0	40
51	Characterization of the molecular mechanisms underlying increased ischemic damage in the aldehyde dehydrogenase 2 genetic polymorphism using a human induced pluripotent stem cell model system. <i>Science Translational Medicine</i> , 2014, 6, 255ra130.	5.8	84
52	Patient-specific pluripotent stem cells in doxorubicin cardiotoxicity: A new window into personalized medicine. <i>Progress in Pediatric Cardiology</i> , 2014, 37, 23-27.	0.2	9
53	Human Stem Cells for Modeling Heart Disease and for Drug Discovery. <i>Science Translational Medicine</i> , 2014, 6, 239ps6.	5.8	175
54	High Efficiency Differentiation of Human Pluripotent Stem Cells to Cardiomyocytes and Characterization by Flow Cytometry. <i>Journal of Visualized Experiments</i> , 2014, , 52010.	0.2	56

#	ARTICLE	IF	CITATIONS
55	Induced Pluripotent Stem Cells from Familial Alzheimer's Disease Patients Differentiate into Mature Neurons with Amyloidogenic Properties. <i>Stem Cells and Development</i> , 2014, 23, 2996-3010.	1.1	75
56	Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as an In Vitro Model for Coxsackievirus B3-Induced Myocarditis and Antiviral Drug Screening Platform. <i>Circulation Research</i> , 2014, 115, 556-566.	2.0	134
57	Chemically defined generation of human cardiomyocytes. <i>Nature Methods</i> , 2014, 11, 855-860.	9.0	1,320
58	A Human Pluripotent Stem Cell Surface N-Glycoproteome Resource Reveals Markers, Extracellular Epitopes, and Drug Targets. <i>Stem Cell Reports</i> , 2014, 3, 185-203.	2.3	73
59	Multi-cellular interactions sustain long-term contractility of human pluripotent stem cell-derived cardiomyocytes. <i>American Journal of Translational Research (discontinued)</i> , 2014, 6, 724-35.	0.0	32
60	MicroRNA-302 Increases Reprogramming Efficiency via Repression of NR2F2. <i>Stem Cells</i> , 2013, 31, 259-268.	1.4	121
61	A Review of Human Pluripotent Stem Cell-Derived Cardiomyocytes for High-Throughput Drug Discovery, Cardiotoxicity Screening, and Publication Standards. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 22-30.	1.1	114
62	Highly Efficient Directed Differentiation of Human Induced Pluripotent Stem Cells into Cardiomyocytes. <i>Methods in Molecular Biology</i> , 2013, 997, 149-161.	0.4	35
63	Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays. <i>Circulation</i> , 2013, 128, S3-13.	1.6	269
64	Generation of Human iPSCs from Human Peripheral Blood Mononuclear Cells Using Non-integrative Sendai Virus in Chemically Defined Conditions. <i>Methods in Molecular Biology</i> , 2013, 1036, 81-88.	0.4	72
65	Molecular Imaging of Stem Cells: Tracking Survival, Biodistribution, Tumorigenicity, and Immunogenicity. <i>Theranostics</i> , 2012, 2, 335-345.	4.6	107
66	Engraftment of human embryonic stem cell derived cardiomyocytes improves conduction in an arrhythmogenic in vitro model. <i>Journal of Molecular and Cellular Cardiology</i> , 2012, 53, 15-23.	0.9	37
67	Production of De Novo Cardiomyocytes: Human Pluripotent Stem Cell Differentiation and Direct Reprogramming. <i>Cell Stem Cell</i> , 2012, 10, 16-28.	5.2	616
68	A Universal System for Highly Efficient Cardiac Differentiation of Human Induced Pluripotent Stem Cells That Eliminates Interline Variability. <i>PLoS ONE</i> , 2011, 6, e18293.	1.1	363
69	Pluripotent stem cell heterogeneity and the evolving role of proteomic technologies in stem cell biology. <i>Proteomics</i> , 2011, 11, 3947-3961.	1.3	20
70	Derivation and characterisation of the human embryonic stem cell lines, NOTT1 and NOTT2. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2010, 46, 367-375.	0.7	8
71	Challenges and strategies for generating therapeutic patient-specific hemangioblasts and hematopoietic stem cells from human pluripotent stem cells. <i>International Journal of Developmental Biology</i> , 2010, 54, 965-990.	0.3	29
72	Improved Human Embryonic Stem Cell Embryoid Body Homogeneity and Cardiomyocyte Differentiation from a Novel V-96 Plate Aggregation System Highlights Interline Variability. <i>Stem Cells</i> , 2007, 25, 929-938.	1.4	275

#	ARTICLE	IF	CITATIONS
73	Hematopoiesis from Human Embryonic Stem Cells: Overcoming the Immune Barrier in Stem Cell Therapies. <i>Stem Cells</i> , 2006, 24, 815-824.	1.4	36
74	Human embryonic stem cells as a model for nutritional programming: An evaluation. <i>Reproductive Toxicology</i> , 2005, 20, 353-367.	1.3	18
75	A physical map of the mouse genome. <i>Nature</i> , 2002, 418, 743-750.	13.7	316